Patents by Inventor Elliot Ehrich

Elliot Ehrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10314838
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ c ma ? ? x ? ( BUP ) / EC 50 ] [ c ma ? ? x ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: June 11, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Patent number: 10195191
    Abstract: The invention relates a composition comprising an opioid agonist and Compound-1:
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: February 5, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Patent number: 10188643
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: January 29, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Publication number: 20180078542
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ c ma ? ? x ? ( BUP ) / EC 50 ] [ c ma ? ? x ? ( ANTAGONIST ) / IC 50 ] .
    Type: Application
    Filed: September 28, 2017
    Publication date: March 22, 2018
    Inventors: Daniel Deaver, Elliot Ehrich
  • Publication number: 20180078543
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Application
    Filed: October 2, 2017
    Publication date: March 22, 2018
    Inventors: Daniel Deaver, Elliot Ehrich
  • Patent number: 9918978
    Abstract: The invention relates to a composition comprising buprenorphine and ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: March 20, 2018
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Patent number: 9913837
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: March 13, 2018
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Publication number: 20180064814
    Abstract: The inventions described herein arose from unexpected discoveries made during clinical trials with a long acting formulation of naltrexone. As such, the invention includes a method for treating an individual in need of naltrexone comprising the step of parenterally administering a long acting formulation comprising naltrexone and to the use of naltrexone in the manufacture of medicaments for use in such methods.
    Type: Application
    Filed: April 13, 2017
    Publication date: March 8, 2018
    Inventor: Elliot Ehrich
  • Publication number: 20170136004
    Abstract: The invention relates a composition comprising an opioid agonist and Compound-1:
    Type: Application
    Filed: November 16, 2015
    Publication date: May 18, 2017
    Inventors: Daniel Deaver, Elliot Ehrich
  • Publication number: 20170119699
    Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
    Type: Application
    Filed: December 23, 2016
    Publication date: May 4, 2017
    Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
  • Publication number: 20170056392
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Application
    Filed: September 12, 2016
    Publication date: March 2, 2017
    Inventors: Daniel Deaver, Elliot Ehrich
  • Patent number: 9498474
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: November 22, 2016
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Publication number: 20160256450
    Abstract: The invention relates to a composition comprising buprenorphine and ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Application
    Filed: March 10, 2016
    Publication date: September 8, 2016
    Inventors: Daniel Deaver, Elliot Ehrich
  • Patent number: 9211293
    Abstract: The invention relates a composition comprising an opioid agonist and Compound-1:
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: December 15, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Publication number: 20150094378
    Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
    Type: Application
    Filed: May 1, 2014
    Publication date: April 2, 2015
    Applicant: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
  • Publication number: 20150051240
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Application
    Filed: July 29, 2014
    Publication date: February 19, 2015
    Inventors: Daniel Deaver, Elliot Ehrich
  • Patent number: 8822488
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUB ) BC 30 ] [ C max ( ANTAGONIST ) IC 30 ] .
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: September 2, 2014
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Patent number: 8747813
    Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: June 10, 2014
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
  • Publication number: 20130253065
    Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
    Type: Application
    Filed: March 6, 2013
    Publication date: September 26, 2013
    Applicant: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
  • Patent number: 8415397
    Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: April 9, 2013
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa